Research Analysts Issue Forecasts for Amgen FY2027 Earnings

Key Points

• Erste Group Bank raised Amgen’s FY2027 EPS forecast to $24.43 from $23.50, above the current full-year consensus estimate of $22.97, while maintaining a “Hold” rating.
• Amgen’s latest quarterly results exceeded expectations, with EPS of $6.29 versus $5.62 expected and revenue of $10.05 billion versus $9.43 billion; quarterly revenue increased 9.5% year over year.
• Analyst sentiment remains mixed but generally supportive: Amgen has an average “Hold” rating and a $380.43 price target, while the company announced a quarterly dividend of $2.52, equivalent to a 2.3% annual yield.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at Erste Group Bank increased their FY2027 EPS estimates for shares of Amgen in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will earn $24.43 per share for the year, up from their previous forecast of $23.50. Erste Group Bank currently has a "Hold" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $22.97 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. During the same period last year, the company earned $6.02 earnings per share. The company's quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

Several other brokerages have also recently issued reports on AMGN. UBS Group boosted their price objective on shares of Amgen from $420.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. BMO Capital Markets increased their target price on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. Morgan Stanley reiterated an "overweight" rating and issued a $362.00 target price on shares of Amgen in a report on Wednesday, August 19th. Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Bank of America upped their price target on Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $380.43.

Amgen Stock Performance

NASDAQ:AMGN opened at $429.88 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company has a market cap of $232.41 billion, a P/E ratio of 26.72, a P/E/G ratio of 3.12 and a beta of 0.41. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $447.03. The firm's 50 day moving average is $390.35 and its two-hundred day moving average is $365.09.

Institutional Trading of Amgen

A number of hedge funds have recently made changes to their positions in AMGN. Brighton Jones LLC boosted its position in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock valued at $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. increased its position in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC increased its position in shares of Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock worth $1,141,000 after acquiring an additional 416 shares during the last quarter. Finally, Ieq Capital LLC lifted its stake in shares of Amgen by 5.1% in the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock worth $15,120,000 after acquiring an additional 2,611 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company's stock.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen's dividend payout ratio is presently 62.65%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha demonstrated a meaningful mortality benefit. Amgen reported that Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. The findings came from a prespecified analysis of the Phase 3 VESALIUS-CV trial presented at the 2026 European Society of Cardiology Congress. The result could support broader use of Repatha beyond cholesterol reduction and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analyst sentiment and performance comparisons remain supportive. Commentary says AMGN has outperformed the broader market over the past year, with analysts moderately bullish on its future prospects. Erste Group Bank also issued a positive forecast for Amgen’s earnings, adding to the favorable outlook. Amgen stock performance comparison
• Neutral Sentiment: Industry growth could provide a secondary opportunity. A new report identifies Amgen among companies participating in the expanding palmoplantar pustulosis market, driven by increased diagnosis and demand for biologic treatments. However, the report does not identify a specific Amgen product or provide a material revenue forecast, so the immediate stock impact is likely limited. Palmoplantar pustulosis market report

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source